

## Northern Light Life Sciences Conference Abstracts – jak si zobrazit poster

Po zobrazení výsledků vyhledávání kliknout na [www odkaz pod Poster URL](#):

**Filter By**

[Add to Search History](#)

Selected Only ( 0 )

**Years**

All Years

Current year

Past 3 years

Past 5 years

Specific Year Range

Author

Publication Type

---

**My Projects**

[+ New Project](#)

No projects available.

Digestive Disease Week 2015

**Abstract URL**  
<https://discovery.northernlight...>

► Abstract [Cite](#) [+ My Projects](#) [+ Annotate](#)

---

3. **131I-MIBG Therapy In the Management of Refractory And Relapsed Neuroblastoma: An Individualised Approach**

S George; SJ Kirk; D Lancaster; SJ Vaidya; H Mandeville; F Saran; S Chittenden; ADJ Pearson; Y Du; GD Flux

**Conference Name**  
European Breast Cancer Conference 2014

**Abstract URL**  
<https://discovery.northernlight...>

**Poster URL**  
<https://discovery.northernlight...>

► Abstract [Cite](#) [+ My Projects](#) [+ Annotate](#)

---

4. **131I-MIBG Therapy In the Management of Refractory And Relapsed Neuroblastoma: An Individualised Approach**

**PLNÝ TEXT**  
Zdroje na Internetu  
LinkSolver

---

Abstract Reference  
Complete Reference

---

**PLNÝ TEXT**  
Zdroje na Internetu  
LinkSolver

---

Abstract Reference  
Complete Reference

Dále mohou nastat tyto dvě situace:

1. Jste přeměrováni přímo na stránky producenta databáze (Northern Light) a v pravé části okna se Vám zobrazí rovnou i náhled posteru:

Northern Light Discovery Portal

**Document Details**

[Actions](#)

[Citation](#) | [Entity Mentions](#)

---

**Title:** TOPICAL ESTROGEN THERAPY IN POSTMENOPAUSAL WOMEN - INDIAN EXPERIENCE

**Conference:** International Society for Pharmacoeconomics and Outcomes Research Asia-Pacific Conference 2012

**Sponsor:** International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

**Authors:** S Donde - Pfizer, Inc.  
G Uchit - Pfizer, Inc.  
N Valanju - M M Hospital

**Conference Opening Date:** 02-Sep-2012

**Conference Ending Date:** 04-Sep-2012

**Location:** Taipei, China

**Direct link:** [http://www.ispor.org/research\\_pdfs/41/pdffiles/PIH2.pdf](http://www.ispor.org/research_pdfs/41/pdffiles/PIH2.pdf)  
*(link may have been discontinued by the website owner)*

---

**Summary**

Local estrogen therapy was effective in relieving the symptoms of moderate-to-severe atrophic vaginitis when used twice weekly. Twelve weeks local estrogen therapy was well tolerated and resulted in beneficial changes in the vaginal tissue and induced an overall genital health pattern more characteristic of the premenopausal state.

---

**MI Analyst tags:** Conferences: International Society for

Stránka: 1 z 1 - Automatická velikost

### TOPICAL ESTROGEN THERAPY IN POSTMENOPAUSAL WOMEN – INDIAN EXPERIENCE

SHAAANTANU S DONDE<sup>1</sup>, GANESH UCHIT<sup>1</sup>, NEELAM VALANJU<sup>2</sup>  
Pfizer Ltd<sup>1</sup>, M M Hospital<sup>2</sup>, Mumbai, India

**BACKGROUND**

- Vaginal atrophy is a common manifestation of estrogen deprivation after the menopause. Significant symptoms include hot flashes, dryness, itching, burning, dryness, and pain, but are not treated to the best of our knowledge.
- Given the limited guidelines for vaginal atrophy, we assessed the use of topical estrogen therapy with moderate-to-severe atrophic vaginitis in the premenopausal women.
- The goal of topical estrogen therapy is to provide relief and improve the quality of life of women with moderate-to-severe atrophic vaginitis and improve their overall health.

**OBJECTIVE**

The aim of this study was to assess the efficacy of treatment with local estrogen in the symptoms of moderate-to-severe atrophic vaginitis in Indian postmenopausal women.

**RATIONALE**

- Local estrogen therapy is a safe and effective treatment for moderate-to-severe atrophic vaginitis. However, the use of topical estrogen therapy is not well established in Indian postmenopausal women.
- According to 20% of the population, moderate-to-severe atrophic vaginitis is a common condition. The aim of this study was to assess the efficacy of treatment with local estrogen in the symptoms of moderate-to-severe atrophic vaginitis in Indian postmenopausal women.

**METHODS**

Seventy-five postmenopausal Indian women with moderate-to-severe atrophic vaginitis were recruited for the study. They were treated with topical estrogen therapy twice weekly for 12 weeks. The primary outcome was the reduction in the symptoms of moderate-to-severe atrophic vaginitis. The secondary outcome was the improvement in the overall genital health pattern. The study was conducted in a tertiary care hospital.

**Treatment Regimen**

The women were treated with topical estrogen therapy (Estring) for 12 weeks. The treatment was well tolerated and resulted in beneficial changes in the vaginal tissue and induced an overall genital health pattern more characteristic of the premenopausal state.

**End Point**

The primary outcome was the reduction in the symptoms of moderate-to-severe atrophic vaginitis. The secondary outcome was the improvement in the overall genital health pattern. The study was conducted in a tertiary care hospital.

**Demographic Profile at Baseline**

Parameter	Value
Age (years)	55.0 (SD 6.0)
Duration of menopause (years)	10.0 (SD 4.0)
Body mass index (BMI)	23.0 (SD 3.0)
Smoking status	10 (13.3%)
Alcohol consumption	0 (0%)

Parameter	Pre-treatment (n=75)	Post-treatment (n=75)	Change from Pre-treatment (n=75)	Significance (p-value)
<b>Bothersome Symptoms</b>				
• Vaginal dryness	60 (80%)	22 (29%)	-38 (51%)	<.001
• Vaginal itching	65 (87%)	20 (27%)	-45 (69%)	<.001
• Vaginal burning	55 (73%)	15 (20%)	-40 (53%)	<.001
• Vaginal pain	40 (53%)	10 (13%)	-30 (39%)	<.001
• Dyspareunia	40 (53%)	10 (13%)	-30 (39%)	<.001
• Overall genital health	10 (13%)	45 (60%)	35 (45%)	<.001
<b>Bothersome Symptoms</b>				
• Vaginal dryness	60 (80%)	22 (29%)	-38 (51%)	<.001
• Vaginal itching	65 (87%)	20 (27%)	-45 (69%)	<.001
• Vaginal burning	55 (73%)	15 (20%)	-40 (53%)	<.001
• Vaginal pain	40 (53%)	10 (13%)	-30 (39%)	<.001
• Dyspareunia	40 (53%)	10 (13%)	-30 (39%)	<.001
• Overall genital health	10 (13%)	45 (60%)	35 (45%)	<.001

**Mean % Reduction of Bothersome Symptoms between Pre and Post Treatment**


**Mean % Reduction of Bothersome Symptoms between Pre and Post Treatments**

Symptom	Pre-treatment (%)	Post-treatment (%)
Vaginal dryness	80	29
Vaginal itching	87	27
Vaginal burning	73	20
Vaginal pain	53	13
Dyspareunia	53	13

2. Jste přeměrováni přímo na stránky producenta databáze (Northern Light), náhled posteru se ale v pravé části okna nezobrazuje. Kliknutím na odkaz **Direct link** se buďto dostanete na [www stránky konference](#), kde je poster dostupný (příklad na obrázku, odkaz na poster ve formátu .jpg) nebo se Vám automaticky nabídne otevření PDF.

Document Details

1311-MIBG Therapy In the Management of Refractory And Relapsed Neuroblastoma: An Individualised Approach  
European CanCer Organization (ECCO) - European Breast Cancer Conference 2014 03/19/2014

Conference: European Breast Cancer Conference 2014   
Sponsor: European CanCer Organization (ECCO)  
Authors: S George - Royal Marsden Hospital  
SJ Kirk - Royal Marsden Hospital  
D Lancaster - Royal Marsden Hospital  
SJ Vaidya - Royal Marsden Hospital  
H Mandeville - Royal Marsden Hospital  
F Saran - Royal Marsden Hospital  
S Chittenden - Royal Marsden Hospital and Institute of Cancer Research  
ADJ Pearson - Royal Marsden Hospital  
Y Du - Royal Marsden Hospital  
GD Flux - Royal Marsden Hospital and Institute of Cancer Research  
Conference Opening Date: 19-Mar-2014  
Conference Ending Date: 21-Mar-2014  
Location: Glasgow, Scotland  
Abstract/Poster Number: 1610  
Direct link: <http://www.poster-submission.com/dataimg/posters/35/high/1610.jpg>  
*(link may have been discontinued by the website owner)*  
Summary: Children with relapsed/refractory neuroblastoma are a

Due to technical reasons Northern Light cannot display the original abstract in this window. You may try to open it by clicking the link below:  
<http://www.poster-submission.com/dataimg/posters/35/high/1610.jpg>

